Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men

Trial Profile

Comparison of the Effects of Teriparatide with those of Risendronate on Lumbar Spine Volumetric Bone Mineral Density in GLucocorticpid-Induced Osteoporosis in Men

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2014

At a glance

  • Drugs Teriparatide (Primary) ; Risedronic acid
  • Indications Corticosteroid-induced osteoporosis
  • Focus Therapeutic Use
  • Acronyms GHDH
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top